Aspirin for cardiovascular disease prevention

Johan H A Janssen and David Henshaw
Med J Aust 2004; 180 (2): . || doi: 10.5694/j.1326-5377.2004.tb05814.x
Published online: 19 January 2004

Johan H A Janssen,* David Henshaw

  • Kalgoorlie Regional Hospital, PO Box 8035, Hannans, Kalgoorlie, WA 6433.

  • 1. Hung J, for the Medical Issues Committee of the National Heart Foundation of Australia. Aspirin for cardiovascular disease prevention. Med J Aust 2003; 179: 147-152. <eMJA full text> <MJA full text>
  • 2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists’ Collaboration. BMJ 2002; 324: 71-86.
  • 3. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003; 41: 961-965.
  • 4. MacDonald TM, Wei L. Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003; 361: 573-574.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.